{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:57:46Z","timestamp":1781143066711,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109461","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:09:10Z","timestamp":1779221350000},"page":"109461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase Ib of repotrectinib plus osimertinib in patients with EGFR\u2013mutated advanced non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"217","author":[{"given":"Andres","family":"Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-1144","authenticated-orcid":false,"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-1947","authenticated-orcid":false,"given":"Antonio","family":"Calles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Azkarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gonzalez-Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0817-3400","authenticated-orcid":false,"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2026.109461_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.lungcan.2026.109461_b0010","doi-asserted-by":"crossref","unstructured":"Bazhenova L, Ismaila N, Abu Rous F, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.J Clin Oncol Off J Am Soc Clin Oncol 2024;42(36):e72\u201386.","DOI":"10.1200\/JCO-24-02133"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109461_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109461_b0020","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0025","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41467-019-09734-5","article-title":"AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy","volume":"10","author":"Bertran-Alamillo","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109461_b0030","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.lungcan.2026.109461_b0035","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12(559):eaaz4589","author":"Nilsson","year":"2020","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109461_b0040","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145099","article-title":"Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer","volume":"132","author":"Nanjo","year":"2022","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.lungcan.2026.109461_b0045","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.lungcan.2026.109461_b0050","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109461_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109461_b0060","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest"},{"issue":"35","key":"10.1016\/j.lungcan.2026.109461_b0065","doi-asserted-by":"crossref","first-page":"15535","DOI":"10.1073\/pnas.1009472107","article-title":"TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer","volume":"107","author":"Yao","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109461_b0070","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-10-2668","article-title":"MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents","volume":"71","author":"Fan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2026.109461_b0075","article-title":"Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC","volume":"109(9):djx014","author":"Chaib","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109461_b0080","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","article-title":"SFK\/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer","volume":"77","author":"Ichihara","year":"2017","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109461_b0085","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/1535-7163.MCT-12-0311","article-title":"Activation of IL-6R\/JAK1\/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation","volume":"11","author":"Kim","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109461_b0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-3379","article-title":"IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.lungcan.2026.109461_b0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ebiom.2018.02.001","article-title":"Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis","volume":"29","author":"Karachaliou","year":"2018","journal-title":"EBioMedicine"},{"issue":"16","key":"10.1016\/j.lungcan.2026.109461_b0100","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/1078-0432.CCR-24-0949","article-title":"FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109461_b0175","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent-","volume":"8","author":"Drilon","year":"2018","journal-title":"Front Mutations. Cancer Discov"},{"issue":"17","key":"10.1016\/j.lungcan.2026.109461_b0110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall Survival with Amivantamab\u2013Lazertinib in EGFR-Mutated Advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109461_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109461_b0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lungcan.2026.109461_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108454","article-title":"A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial","volume":"202","author":"Soo","year":"2025","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109461_b0135","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2026.109461_b0140","unstructured":"Park S, Kim TM, Han J-Y, et al. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol [Internet] 2024 [cited 2026 Jan 27];Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.01891."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109461_b0145","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109461_b0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","volume":"332","author":"HARMONi-A Study Investigators","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109461_b0155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2026.109461_b0165","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study","volume":"43(16_suppl):8506\u20138506","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109461_b0180","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/cas.15736","article-title":"Pharmacokinetic and dose\u2010finding study of osimertinib in patients with impaired renal function and low body weight","volume":"114","author":"Fujiwara","year":"2023","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109461_b0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-016-2992-z","article-title":"Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies","volume":"77","author":"Planchard","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109461_b0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109461_b0195","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/psp4.70036","article-title":"A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","volume":"14","author":"Du","year":"2025","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109461_b0200","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7842","key":"10.1016\/j.lungcan.2026.109461_b0205","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","article-title":"Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis","volume":"589","author":"Pastushenko","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0210","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1038\/s41467-018-04590-1","article-title":"Assembly and activation of the Hippo signalome by FAT1 tumor suppressor","volume":"9","author":"Martin","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109461_b0215","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/2159-8290.CD-20-1385","article-title":"Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo","volume":"11","author":"Foggetti","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.lungcan.2026.109461_b0220","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109461_b0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41698-024-00557-2","article-title":"TP53 gain-of-function mutations promote osimertinib resistance via TNF-\u03b1\u2013NF-\u03baB signaling in EGFR-mutated lung cancer","volume":"8","author":"Ibusuki","year":"2024","journal-title":"Npj Precis Oncol"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109461_b0230","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1172\/JCI96148","article-title":"TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer","volume":"128","author":"Gong","year":"2018","journal-title":"J Clin Invest"},{"issue":"7339","key":"10.1016\/j.lungcan.2026.109461_b0235","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"Bivona","year":"2011","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109461_b0240","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109461_b0245","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2026.109461_b0250","unstructured":"Lu S, Wang J, Yang N, et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. The Lancet [Internet] 2026 [cited 2026 Jan 19];0(0). Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(25)01811-2\/abstract?rss=yes."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:11:35Z","timestamp":1781140295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S0169500226005222"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109461","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib of repotrectinib plus osimertinib in patients with EGFR\u2013mutated advanced non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109461"}}